· Published by Health Canada · Official notice
This is duplicated text of a letter from Abbott Laboratories Limited
Contact the company for a copy of any references, attachments or enclosures.
December 16th, 2002
Dear Colleagues,
An article was recently published in the November issue of the journal Pediatrics entitled "Reported Adverse Drug Events in Infants and Children Under 2 Years of Age".Footnote 1 The authors' primary message is that (1) adverse events in children are underreported and (2) that drugs are often marketed without studies assessing their safe use in children. In this article, palivizumab is listed as the most commonly cited drug as principal suspect for serious or fatal outcome in children under the age of 2, despite the fact that neither of these concerns apply to palivizumab. Palivizumab has been studied exclusively in high-risk pediatric populations. Several postmarketing programs including prospective adverse event data collection have been conducted.Footnote 2 Footnote 3 Footnote 4 Footnote 5 These programs have produced more complete data collection of adverse events than the passive reporting systems criticized in this paper.
Furthermore, the data as presented are misleading and may cause clinicians and parents to draw erroneous conclusions regarding the safety of palivizumab. It is important to provide assessment of this publication, and place these data in the proper context. It is noteworthy to mention that the authors themselves state that MedWatch reports do not establish a causal link between the event and the medication, and their study does not provide sufficient information to evaluate the risks and benefits of any specific drug, or to form proper justification for identifying the need for new or additional warnings in the prescribing information.
The following details are for your consideration in evaluating this article:
When all of the relevant data available is utilized, and all of the appropriate methods by which safety data is collected are included, the safety profile of palivizumab is again affirmed.
We hope you have found this letter informative and comprehensive. However, if you have any questions or wish to discuss this issue further, please do not hesitate to contact Abbott Laboratories' Medical Information department.
Sincerely,
original signed by
Rafik Zakhari, M.D.
Medical Director,
Abbott Laboratories, Limited
Abbott Laboratories, Limited / Laboratories Abbott, Limitée
P.O. Box / C.P. 6150, Station / succursale Centre-ville
Montréal (Québec) H3C 3K6
References
Moore, TJ, Weiss, S, Kaplan, S, Blaisdell, CJ. Reported Adverse Drug Events in Infants and Children Under 2 Years of Age PEDIATRICS 2002, 110: e53.
Cohen A, Hirsch RL, Sorrentino M, Top F, Carlin D, McClain B and the Synagis Outcomes Survey Group. First year experience using Synagis® (palivizumab) humanized monoclonal antibody for protection from RSV lower respiratory tract infection. 2nd World Congress of Pediatric Infectious Diseases, November 2-6, 1999.
Cohen A and Sorrentino M. Effectiveness of palivizumab for preventing serious RSV disease. Journal of Respiratory Diseases for Pediatricians. 2000;2 (Suppl 4):S30-S32.
Hudak M, et al. Synagis® (palivizumab) prophylaxis of respiratory syncytial virus (RSV) infection - patient demographics and preliminary results from the 2000-2001 Synagis® Outcomes Registry. J Perinatol. 2001; 21:500.
Hudak, M et al. Palivizumab prophylaxis of RSV disease - Results of 5,097 children - The 2001-2002 Outcomes Registry. Journal of Perinatology 2002;22:619.
Connor, E.M., et al. Safety Surveillance in Children Treated with Palivizumab (PLV). J Perinatol. 2002;52:619
Oh, P.I. et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J, 2002;21:512-8.
Connor EM and the Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
CDC: Deaths: Preliminary data for 2000. National Vital Statistics Report. Vol. 49, No. 12; October 9, 2001.
CDC: Infant mortality statistics from the 1998 period linked birth/infant death data set. National Vital Statistics Report Update. Vol. 48, No. 12; July 20, 2000.
Any suspected adverse reactions can also be reported to:>
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0201C2
OTTAWA, Ontario, K1A 1B9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the TPD web site or in The Canadian Compendium of Pharmaceuticals and Specialties.